General Updates

16th July, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, Dalal Street, G Block, Bandra-Kurla Complex Fort, Mumbai – 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543318 Trading Symbol: CLEAN Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “LODR Regulations”) and Clean Science and Technology Limited’s (the “Company”) policy on determination of materiality, we hereby inform the stock exchanges that its wholly owned subsidiary, Clean-Fino Chem Limited (the “Subsidiary”), has entered into definitive agreements for a long-term strategic collaboration with Geneus Chem AG, a company incorporated under the laws of Switzerland, having its office at Mattenstrasse 22, 4058 Basel, Switzerland (“GC”). The collaboration is in line with the Company’s business strategy and is expected to support its specialty chemicals portfolio. Lodha Capital Markets Ltd acted as the financial advisor and AZB & Partners as the legal advisor to the Company for this strategic collaboration agreement. The details required under Regulation 30 read with Schedule III of the LODR Regulations are enclosed as Annexure A, Annexure B and Annexure C below. The intimation is also being uploaded on the website of the Company at www.cleanscience.co.in You are requested to take above information on record. Thanking You. For Clean Science and Technology Limited Ruchita Vij Company Secretary & Compliance Officer Annexure A AGREEMENT TO ACQUIRE Details required under Regulation 30 read with Schedule III of the SEBI (LODR) Regulations, 2015 Sr. Particulars Details 1. Name of the target entity, details in Target entity is Geneus Chem AG a company brief such as size, turnover etc. incorporated under the laws of Switzerland, having its office at Mattenstrasse 22, 4058 Basel, Switzerland (“GC”). GC is a start-up company which was incorporated in 2022. Based on the information available with the Company, GC is not operating at a significant scale including in terms of revenues. 2. Whether the acquisition would fall The Subsidiary has entered into a long-term within related party transaction(s) manufacturing/ supply agreement with GC in terms and whether the promoter/ of which the Subsidiary has agreed to manufacture promoter group/ group companies advanced grades of HALS Products. have any interest in the entity being acquired? In lieu of above collaboration, GC has agreed to issue warrants to the Subsidiary which are If yes, nature of interest and details exercisable by the Subsidiary within the exercise thereof and whether the same is period. d one at “arm’s length” The agreement to acquire does not constitute a related party transaction/ None of the promoters/ promoter group/ group companies have any interest in GC. 3. Industry to which the entity being GC is engaged in the business of research, acquired belongs development, sales, manufacturing, trading, export and import of chemical products as well as consulting and analytical services in this, in particular, with advanced grades of HALS Products. 4. Objects and impact of acquisition The Subsidiary has entered into long term (including but not limited to, collaboration with GC for supply of advance grade disclosure of reasons for of HALS. The collaboration is in line with the acquisition of target entity, if its Company’s business strategy and is expected to business is outside the main line of support its specialty chemicals portfolio. b usiness of the listed entity) 5. Brief details of any governmental No governmental or regulatory approvals are or regulatory approvals required required for the proposed acquisition of GC by the f or the acquisition S ubsidiary. 6. Indicative time period for The share warrants proposed to be issued to the completion of the acquisition. Subsidiary by GC in terms of the Subscription Agreement are exercisable within four years from t he date of issuance of such share warrants by GC. 7. Consideration - whether cash At the time of exercise of the share warrants by the consideration or share swap or any Subsidiary, the Subsidiary will be required to pay a o ther form and details of the same nominal price per company share to GC. 8. Cost of acquisition and/or the price The share warrants proposed to be issued to the at which the shares are acquired Subsidiary by GC in terms of the subscription agreement are exercisable within four years from the date of issuance of such share warrants by GC. No consideration is payable by the Subsidiary for subscription to share warrants. 9. Percentage of shareholding / Upon exercise of the share warrants, the Subsidiary control acquired and / or number will acquire 25% of the share capital of GC on a fully of shares acquired diluted basis. 10. Brief background about the entity GC is Swiss company which was incorporated in acquired in terms of products/line 2022. of business acquired, date of incorporation, history of last 3 GC is engaged in the business of research, years turnover, country in which development, sales, manufacturing, trading, export the acquired entity has presence and import of chemical products as well as and any other significant consulting and analytical services in this, in information (in brief). particular, with advanced grades of HALS Products. Based on the information available with the Company, GC is not operating at a significant scale including in terms of revenues. ANNEXURE B DISCLOSURES UNDER PARA 5A OF PARA A OF PART A OF SCHEDULE III Details required under Regulation 30 read with Schedule III of the SEBI (LODR) Regulations, 2015 Sr. Particulars Details 1. If the listed entity is a party to the Not applicable. The Company is not party to the agreement, definitive agreements. The definitive agreements have been executed with the Subsidiary. (i) details of the counterparties (including name and relationship with the listed entity); 2. If listed entity is not a party to the (a) Clean-Fino Chem Limited, wholly owned agreement, subsidiary of the Company is party to the definitive agreements. (i) name of the party entering into such an (b) Other parties to the definitive agreements are agreement and the GC and the co-founders of GC. GC and the co- relationship with the founders are not related to the Company. listed entity; (c) The definitive agreements have been executed (ii) details of the on July 16, 2026. counterparties to the agreement (including name and relationship with the listed entity); (iii) date of entering into the agreement 3. Purpose of entering into the The definitive agreements have been executed in agreement. relation to a long term strategic collaboration with GC. 4. Shareholding, if any, in the entity The Company does not hold any shares in GC. with whom the agreement is executed. 5. Significant terms of the The definitive agreements are on customary agreement (in brief) commercial terms for a long-term supply collaboration and include, inter alia, provisions relating to minimum offtake commitments, pricing mechanism, product specifications, non-compete obligations, supply obligations, confidentiality, intellectual property, representations and warranties, indemnities, term and termination, and dispute resolution thereof. 6. Extent and the nature of impact Not applicable on management or control of the listed entity. 7. Details and quantification of the Please refer to para (5) above. restriction or liability imposed upon the listed entity. 8. Whether, the said parties are Other than the Subsidiary, the other parties to the related to promoter/promoter definitive agreements are not related to the Company. group/ group companies in any manner. If yes, nature of relationship. 9. Whether the transaction would Not applicable fall within related party transactions? If yes, whether [Showing first 8,000 characters — download PDF for full document]